Showing results (131-140 of 147) with videos related to
Sort By:
Pageof 15
Pharmacogenomics|September 13, 2023
Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancerNathan D Seligson, Jill M Kolesar, Benish Alam, et al.Translational Oncology|October 5, 2023
Gene partners of the EWSR1 fusion may represent molecularly distinct entitiesVictoria Walker, Dexter X Jin, Sherri Z Millis, et al.The Oncologist|December 14, 2018
<i>BRCA1/2</i> Functional Loss Defines a Targetable Subset in LeiomyosarcomaNathan D Seligson, Esko A Kautto, Edward N Passen, et al.Clinical Orthopaedics and Related Research|October 1, 1993
Comparison of the clinical efficacy and tolerance of gentamicin PMMA beads on surgical wire versus combined and systemic therapy for osteomyelitisJ D Blaha, J H Calhoun, C L Nelson, et al.NPJ Precision Oncology|April 26, 2022
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomasNathan D Seligson, Joy Tang, Dexter X Jin, et al.Frontiers in Pharmacology|January 23, 2024
<i>CYP3A5</i> influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantationNathan D Seligson, Xunjie Zhang, Mark C Zemanek, et al.Pharmacogenomics|July 29, 2025
From bench to bedside: a spotlight on pharmacogenomics at Nemours Children's HealthKelsey J Cook, Nathan D Seligson, Benjamin Q Duong, et al.Cancers|November 9, 2024
Correction: Nelson et al. <i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> 2021, <i>13</i>, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.Cancers|April 3, 2021
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.Haematologica|March 2, 2023
<i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplantMelissa Thomas, Junan Li, Kevan King, et al.Pageof 15